Published in: Drug

Elevidys™ (delandistrogene moxeparvovec-rokl)

Full Name	Elevidys™ (delandistrogene moxeparvovec-rokl)
Drug	Elevidys
Manufacturer	Sarepta Therapeutics, Inc.
Route of Administration	Intravenous
Site of Care	Healthcare Facility
Approved Indication	Treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age: For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene
Disease	Duchenne muscular dystrophy (DMD)
Therapeutic Area	Neurology, Genetics
Enrollment Form Link	Enrollment Form
Phone Number	800-870-8931
Fax Number	877-694-2546
Product Website	elevidyshcp.com